CRCT heads into the post-earnings stretch with an unusual split: the stock is quietly recovering, short interest remains elevated, and yet options traders have turned sharply bullish — a divergence that makes the current setup worth watching closely.
The options picture is the most striking signal this week. Traders have shifted decisively toward calls, with the put/call ratio dropping to just 0.082 — well below its 20-day average of 0.160 and close to the lowest reading of the past year (52-week low: 0.068). That's a near-complete collapse in demand for downside protection, with the PCR running almost one standard deviation below normal. The shift is notable given that the stock only just reported earnings on August 4. Whatever the market expected from that print, the options response suggests the reaction was treated as a clearing event rather than a new catalyst for concern.
Short interest tells a more cautious story. At 11.1% of the free float, CRCT carries a meaningful short position — roughly 5.9 million shares — and that figure has crept up about 3.4% over the past week even as the stock gained 5.2% to $4.94. The borrow market, however, is not signalling any squeeze pressure. Availability is running at 162%, well within the normal range, and cost to borrow has fallen sharply — down over 31% in the past month to just 0.83%. The 52-week tightest availability reading was 136% back on July 7; since then the lending pool has loosened considerably. Short sellers are rebuilding positions at a moderate pace, but financing conditions give them no urgency to cover. The ORTEX short score of 75.2 — near its recent range high — confirms this is a name with sustained bearish conviction behind it.
The Street has been consistently negative on CRCT, and that tone has not shifted. The mean analyst price target is $3.82 against a current price of $4.94, implying the consensus view is that the stock is already overvalued at current levels. The most recent analyst action of note came from Goldman Sachs in January, maintaining a Sell with a $3.00 target — the stock has since traded above that level, but the directional call remains intact. Morgan Stanley and Citigroup both carry Underweight and Sell ratings respectively. All three major covering firms have been cutting targets consistently since 2023, with no upgrades on record. Factor scores reinforce the bearish lean: the short score ranks in the 2nd percentile of the universe, meaning almost no stock has a more bearish short-side setup. EPS momentum scores are weak — 11th percentile over 30 days, 21st over 90 days — though the EPS surprise score is a genuine outlier at the 95th percentile, suggesting the company has beaten low expectations repeatedly even as the underlying trend deteriorates.
Insider activity adds another layer of caution. CEO Ashish Arora has been selling consistently since May. The largest single-day sale was 203,403 shares at $4.03 on May 15, generating roughly $820,000. He has continued selling in smaller clips through mid-July, including two transactions last month at around $4.75. CFO Kimball Shill also sold in May. The 90-day net insider position is a positive 501,000 shares — which at first appears bullish — but the ownership table clarifies the picture: Arora himself holds 29.5 million shares (14% of the company), meaning his incremental sells represent a tiny fraction of his stake while the directional signal from every recent transaction is firmly one-way. Petrus Trust, the controlling vehicle, holds 57.6% of shares and trimmed its position by 2.1 million shares in Q1.
The next earnings date is November 3, and the stock's post-print behaviour this week — up 3.1% on the day results dropped and 5.2% on the week — will be the data point to carry forward into that setup. Whether options traders maintain their unusually bullish lean as the stock tests resistance near $5.00, and whether short sellers continue adding at these levels, is the tension that defines the coming weeks.
See the live data behind this article on ORTEX.
Open CRCT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
